Sign up
Pharma Capital

Orgenesis teams up with HemoGenyx to develop its AHC platform in ‘exciting’ deal

In part one of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx Pharmaceuticals Plc (LON:HEMO), CEO Vered Caplan of Orgenesis and CEO Vladislav Sandler of HemoGenyx tell Proactive Investors the two biopharmas will work together to further develop and commercialize Hemogenyx’s advanced hematopoietic chimeras (AHC) – a new type of humanized mouse with a functional human immune system.

Cell therapy specialist Orgenesis will invest $1million as part of a new collaboration deal with biopharma HemoGenyx.

 

View full ORGS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.